结果与展望
抗病毒药物种类繁多,机制复杂,比如抗HIV药物,FDA批准的药物就有8大类50几种(含药代动力学增强剂和复合制剂),分别为核苷类反转录酶抑制剂(NRTIs)、非核苷类反转录酶抑制剂(NNRTIs)、蛋白酶抑制剂(PIs)、整合酶抑制剂(INSTIs)、融合抑制剂(FIs)、CCR5受体拮抗剂、CD4定向附着后抑制剂(单克隆抗体)和附着抑制剂。国内上市的药物亦有NRTIs、NNRTIs、PIs、INSTIs和FIs五大类(包含复合制剂)。
有些药物同时兼具多种抗病毒活性,也有些药物的潜在功能和作用机制仍在探究中,因此分类方式也可能略有差异。病毒寄生于宿主细胞内,能抑制或杀灭病毒的药物一般也会损伤宿主细胞,因此多数抗病毒药物选择性低,毒性大,临床疗效也不十分理想。在药物的使用上要特别注意毒性反应和副作用,遵循医嘱,合理使用药物。由于病毒的高度变异性,耐药性问题给抗病毒药物的研制带来很大挑战,联合用药是目前对抗许多耐药病毒感染的重要疗法。寻找安全有效的抗病毒药仍然是抗病毒药物研究的热点。
(谢美榕 吴守丽)
参考文献
[1]国家药典委员会.中华人民共和国药典 (2020年版) [M].北京:中国医药科技出版社,2020.
[2]陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011.
[3]Poveda E,Briz V,Soriano V.Enfuvirtide,the first fusion inhibitor to treat HIV infection[J].AIDS Rev,2005,7 (3) :139-147.
[4]Sayana S,Khanlou H.Maraviroc:a new CCR5 antagonist[J].Expert Rev Anti Infect Ther,2009,7 (1) :9-19.DOI:10.1586/14787210.7.1.9.
[5]Wu H,Yao C,Su B,et al.Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1:interim 48week results from the randomized,controlled,phase 3 trial,non-inferiority TALENT study.2018.
[6]Cahn P,Fink V,Patterson P.Fostemsavir:a new CD4 attachment inhibitor[J].Curr Opin HIV AIDS,2018.13(4):341–345.DOI:10.1097/COH.0000000000000469.
[7]Furuta Y,Komeno T,Nakamura T:Favipiravir (T-705),a broad spectrum inhibitor of viral RNA polymerase[J].Proc Jpn Acad Ser B Phys Biol Sci,2017,93 (7) :449-463.DOI:10.2183/pjab.93.027.
[8]Warren TK,Jordan R,Lo MK,et al:Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J].Nature,2016,531 (7594) :381-385.DOI:10.1038/nature17180.(https://www.daowen.com)
[9]Yarchoan R,Broder S.Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders.N Engl J Med[J].1987,316 (9) :557-564.DOI:10.1056/NEJM198702263160925.
[10]Waters LJ,Mandalia S,Gazzard B,et al.Prospective HLA-B*5701 screening and abacavir hypersensitivity:a single centre experience[J].AIDS,2007,21 (18) :2533-2534.DOI:10.1097/QAD.0b013e328273bc07.
[11]Fung HB,Stone EA,Piacenti FJ.Tenofovir disoproxil fumarate:a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection[J].Clin Ther,2002,24 (10) :1515-1548.
[12]Adkins JC,Noble S.Efavirenz[J].Drugs,1998,56 (6) :1055-1066.DOI:10.2165/00003495-199856060-00014.
[13]Correll T,Klibanov OM.Integrase inhibitors:a new treatment option for patients with human immunodeficiency virus infection[J].Pharmacotherapy,2008,28 (1) :90-101.DOI:10.1592/phco.28.1.90
[14]Larson KB,Wang K,Delille C,et al.Pharmacokinetic enhancers in HIV therapeutics[J].Clin Pharmacokinet,2014,53 (10) :865-872.DOI:10.1007/s40262-014-0167-9.
[15]Scott LJ.Peramivir:A Review in Uncomplicated Influenza[J].Drugs,2018,78 (13) :1363-1370.DOI:10.1007/s40265-018-0981-8.
[16]Bang LM,Scott LJ.Emtricitabine:an antiretroviral agent for HIV infection[J].Drugs,2003,63 (22) :2413-2426.
[17]American Association for the Study of Liver Diseases,Infectious Diseases Society of America.HCV guidance[EB/OL].(2017-06-12)[2020-03-01].http://hcvguidelines.org.Accessed June 12,2017.
[18]Lawitz EJ,Dvory-Sobol H,Doehle BP,et al.Clinical Resistance to Velpatasvir(GS-5816),a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein[J].Antimicrob Agents Chemother,2016,22,60 (9) :5368-5378.DOI:10.1128/AAC.00763-16.
[19]Meanwell NA,Krystal MR,Nowicka-Sans B,et al.Inhibitors of HIV-1 Attachment:The Discovery and Development of Temsavir and its Prodrug Fostemsavir[J].J Med Chem.2018,61 (1) :62-80.DOI:10.1021/acs.jmedchem.7b01337.